胃癌外科治疗的新进展及发展趋势

doi:10.19401/j.cnki.1007-3639.2024.03.002

摘要/Abstract

摘要：

胃癌严重威胁人类健康，尽管近年来化疗、靶向治疗和免疫治疗等新型药物研发不断取得突破，但根治性手术始终是胃癌诊疗的核心。随着标准胃癌根治手术的成型，以腹腔镜技术为代表的微创外科治疗技术的进步，进展期胃癌围手术期综合治疗模式的确定，以及胃癌精准外科理念的形成和初步实践，胃癌手术治疗取得了巨大进步。个体化和精准化胃癌外科治疗理念深入人心。安全、有效、精准、微创始终是胃癌外科医师需牢牢把握的学科发展的内在规律。为帮助年轻医师更好的成长，本文总结胃癌诊疗的最新进展，并对未来的发展趋势进行展望。

关键词: 胃癌, 外科治疗, 进展, 趋势

Abstract:

Gastric cancer poses a serious threat to the health of people. Despite the continuous breakthroughs in the development of new drugs such as chemotherapy, targeted therapy and immunotherapy in recent years, radical surgery remains the cornerstone in the treatment of gastric cancer. With the establishment of standard gastric cancer surgery, the advancement of minimally invasive surgical techniques represented by laparoscopy, the determination of perioperative comprehensive treatment of advanced gastric cancer and the formation and initial practice of precise surgical concepts for gastric cancer, the progress of surgical treatment for gastric cancer is advancing by leaps and bounds. The concepts of individualized and optimal treatment are gradually taking root. Safety, effectiveness, precision and minimally invasive approaches have always been the inherent laws of discipline development firmly grasped by gastric cancer surgeons. In order to facilitate better growth for young doctors, the author summarized the latest developments in the diagnosis and treatment of gastric cancer and looked ahead to future trend.

Key words: Gastric cancer, Surgical treatment, Progress, Trend

中图分类号:

R735.2

汪学非, 周鹏, 唐兆庆. 胃癌外科治疗的新进展及发展趋势[J]. 中国癌症杂志, 2024, 34(3): 250-258.

WANG Xuefei, ZHOU Peng, TANG Zhaoqing. New progress and development trend of surgical treatment for gastric cancer[J]. China Oncology, 2024, 34(3): 250-258.

图/表 1

参考文献 55

[1]	ZHENG R S, CHEN R, HAN B F, et al. Cancer incidence and mortality in China, 2022[J]. Zhonghua Zhong Liu Za Zhi, 2024, 46: 221-231.
[2]	YANG W J, ZHAO H P, YU Y, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer[J]. World J Gastroenterol, 2023, 29(16): 2452-2468. doi: 10.3748/wjg.v29.i16.2452
[3]	SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396 (10251): 635-648. doi: S0140-6736(20)31288-5 pmid: 32861308
[4]	SATO H, NOSHIRO H. Report about the present condition of Billroth’s stomach specimens[J]. Gastric Cancer, 2019, 22(6): 1310-1311. doi: 10.1007/s10120-019-00987-z
[5]	GHOSSAIN A, GHOSSAIN M A. History of mastectomy before and after Halsted[J]. J Med Liban, 2009, 57(2): 65-71.
[6]	日本胃癌学会. 胃癌处理规约[M]. 10版. 东京: 金原出版株式会社, 1979.
	Japanese Gastric Cancer Association. Gastric cancer management protocol[M]. 10 edition. Tokyo: Kanehara Publishing Co., LTD, 1979.
[7]	CUSCHIERI A, FAYERS P, FIELDING J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group[J]. Lancet, 1996, 347(9007): 995-999. doi: 10.1016/s0140-6736(96)90144-0 pmid: 8606613
[8]	BONENKAMP J J, HERMANS J, SASAKO M, et al. Extended lymph-node dissection for gastric cancer[J]. N Engl J Med, 1999, 340(12): 908-914. doi: 10.1056/NEJM199903253401202
[9]	SONGUN I, PUTTER H, KRANENBARG E M, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5): 439-449. doi: 10.1016/S1470-2045(10)70070-X pmid: 20409751
[10]	SASAKO M, SANO T, YAMAMOTO S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer[J]. N Engl J Med, 2008, 359(5): 453-462. doi: 10.1056/NEJMoa0707035
[11]	TSUBURAYA A, MIZUSAWA J, TANAKA Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis[J]. Br J Surg, 2014, 101(6): 653-660. doi: 10.1002/bjs.9484 pmid: 24668391
[12]	KUROKAWA Y, TAKEUCHI H, DOKI Y, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study[J]. Ann Surg, 2021, 274(1): 120-127. doi: 10.1097/SLA.0000000000003499
[13]	徐泽宽, 李铮, 徐皓. 从2023年国际胃癌大会看胃癌外科治疗进展与发展趋势[J]. 中国实用外科杂志, 2023, 43(9): 971-974.
	XU Z K, LI Z, XU H. Progress and trends of surgical treatment for gastric cancer from the International Gastric Cancer Congress 2023(IGCC 2023)[J]. Chin J Pract Surg, 2023, 43(9): 971-974.
[14]	KITANO S, ISO Y, MORIYAMA M, et al. Laparoscopy-assisted billroth Ⅰ gastrectomy[J]. Surg Laparosc Endosc, 1994, 4(2): 146-148.
[15]	YOUNG K, MO H, LEE H H, et al. Laproscopic surgery for gastric cancer[M]//Management of Gastric Cancer. InTech, 2011.
[16]	KIM H H, HAN S U, KIM M C, et al. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage Ⅰ gastric cancer: the KLASS-01 randomized clinical trial[J]. JAMA Oncol, 2019, 5(4): 506-513. doi: 10.1001/jamaoncol.2018.6727
[17]	KATAI H, MIZUSAWA J, KATAYAMA H, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(2): 142-151.
[18]	YU J, HUANG C M, SUN Y H, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial[J]. JAMA, 2019, 321(20): 1983-1992. doi: 10.1001/jama.2019.5359
[19]	HYUNG W J, YANG H K, HAN S U, et al. A feasibility study of laparoscopic total gastrectomy for clinical stage Ⅰ gastric cancer: a prospective multi-center phase Ⅱ clinical trial, KLASS 03[J]. Gastric Cancer, 2019, 22(1): 214-222. doi: 10.1007/s10120-018-0864-4
[20]	KATAI H, MIZUSAWA J, KATAYAMA H, et al. Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage Ⅰ gastric cancer: Japan Clinical Oncology Group study JCOG1401[J]. Gastric Cancer, 2019, 22(5): 999-1008. doi: 10.1007/s10120-019-00929-9
[21]	LIU F L, HUANG C M, XU Z K, et al. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰ gastric cancer: the CLASS02 multicenter randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1590-1597. doi: 10.1001/jamaoncol.2020.3152
[22]	HASHIZUME M, KONISHI K, TSUTSUMI N, et al. A new era of robotic surgery assisted by a computer-enhanced surgical system[J]. Surgery, 2002, 131(1 Suppl): S330-S333.
[23]	LI Z Y, ZHOU Y B, LI T Y, et al. Robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: a multicenter cohort study of 5 402 patients in China[J]. Ann Surg, 2023, 277(1): e87-e95.
[24]	OJIMA T, NAKAMURA M, HAYATA K, et al. Short-term outcomes of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer: a randomized clinical trial[J]. JAMA Surg, 2021, 156(10): 954-963. doi: 10.1001/jamasurg.2021.3182
[25]	ZONG L, ABE M, SETO Y, et al. The challenge of screening for early gastric cancer in China[J]. Lancet, 2016, 388(10060): 2606.
[26]	中国胃肠肿瘤外科联盟. 中国胃肠肿瘤外科联盟数据报告(2014—2016)[J]. 中国实用外科杂志, 2018, 38(1): 90-93. doi: 10.19538/j.cjps.issn1005-2208.2018.01.20
	China Gastrointestinal Cancer Surgery Union. Data report of China Gastrointestinal Cancer Surgery Union (2014-2016)[J]. Chin J Pract Surg, 2018, 38(1): 90-93.
[27]	SASAKO M, SANO T, YAMAMOTO S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial[J]. Lancet Oncol, 2006, 7(8): 644-651. doi: 10.1016/S1470-2045(06)70766-5 pmid: 16887481
[28]	SANO T, SASAKO M, MIZUSAWA J, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma[J]. Ann Surg, 2017, 265(2): 277-283. doi: 10.1097/SLA.0000000000001814 pmid: 27280511
[29]	KUROKAWA Y, DOKI Y, MIZUSAWA J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(7): 460-468.
[30]	SAKURAMOTO S, SASAKO M, YAMAGUCHI T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine[J]. N Engl J Med, 2007, 357(18): 1810-1820. doi: 10.1056/NEJMoa072252
[31]	BANG Y J, KIM Y W, YANG H K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J]. Lancet, 2012, 379(9813): 315-321. doi: 10.1016/S0140-6736(11)61873-4
[32]	CUNNINGHAM D, ALLUM W H, STENNING S P, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20. doi: 10.1056/NEJMoa055531
[33]	AL-BATRAN S E, HOMANN N, PAULIGK C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial[J]. Lancet, 2019, 393(10184): 1948-1957. doi: 10.1016/S0140-6736(18)32557-1
[34]	ZHANG X T, LIANG H, LI Z Y, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial[J]. Lancet Oncol, 2021, 22(8): 1081-1092. doi: 10.1016/S1470-2045(21)00297-7
[35]	KANG Y K, YOOK J H, PARK Y K, et al. PRODIGY: a phase Ⅲ study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer[J]. J Clin Oncol, 2021, 39(26): 2903-2913. doi: 10.1200/JCO.20.02914
[36]	BANG Y J, VAN CUTSEM E, FEYEREISLOVA A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697. doi: 10.1016/S0140-6736(10)61121-X
[37]	SHAH M A, SHITARA K, AJANI J A, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial[J]. Nat Med, 2023, 29(8): 2133-2141. doi: 10.1038/s41591-023-02465-7 pmid: 37524953
[38]	HOFHEINZ R D, HEGEWISCH-BECKER S, KUNZMANN V, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase Ⅱ trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group[J]. Int J Cancer, 2021, 149(6): 1322-1331. doi: 10.1002/ijc.v149.6
[39]	RIVERA F, IZQUIERDO-MANUEL M, GARCÍA-ALFONSO P, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase Ⅱ trial[J]. Eur J Cancer, 2021, 145: 158-167. doi: 10.1016/j.ejca.2020.12.005
[40]	JANJIGIAN Y Y, SHITARA K, MOEHLER M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. doi: 10.1016/S0140-6736(21)00797-2 pmid: 34102137
[41]	SHITARA K, VAN CUTSEM E, BANG Y J, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580. doi: 10.1001/jamaoncol.2020.3370
[42]	SHITARA K, MOEHLER M H, AJANI J A, et al. Nivolumab (NIVO)+ chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649[C]. Chicago: ASCO, 2024.
[43]	XU J M, JIANG H P, PAN Y Y, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial[J]. JAMA, 2023, 330(21): 2064-2074. doi: 10.1001/jama.2023.19918 pmid: 38051328
[44]	TERASHIMA M, KANG Y K, KIM Y W, et al. ATTRACTION-5: a phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage Ⅲ (pStage Ⅲ) gastric or gastroesophageal junction (G/GEJ) cancer[J]. J Clin Oncol, 2023, 41(16_suppl): 4000.
[45]	SHITARA K, RHA S Y, WYRWICZ L S, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study[J]. Lancet Oncol, 2024, 25(2): 212-224. doi: 10.1016/S1470-2045(23)00541-7 pmid: 38134948
[46]	JANJIGIAN Y Y, AL-BATRAN S E, WAINBERG Z A, et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study[J]. J Clin Oncol, 2024, 42(3_suppl): LBA246.
[47]	JANJIGIAN Y Y, KAWAZOE A, BAI Y X, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial[J]. Lancet, 2023, 402(10418): 2197-2208. doi: 10.1016/S0140-6736(23)02033-0 pmid: 37871604
[48]	AL-BATRAN S E, HOMANN N, PAULIGK C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial[J]. JAMA Oncol, 2017, 3(9): 1237-1244. doi: 10.1001/jamaoncol.2017.0515
[49]	LUO H Y, XU G L, LI C F, et al. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study[J]. Lancet Oncol, 2019, 20(12): 1645-1654. doi: S1470-2045(19)30637-0 pmid: 31591062
[50]	DONG D, FANG M J, TANG L, et al. Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study[J]. Ann Oncol, 2020, 31(7): 912-920. doi: S0923-7534(20)39294-2 pmid: 32304748
[51]	DONG D, TANG L, LI Z Y, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer[J]. Ann Oncol, 2019, 30(3): 431-438. doi: S0923-7534(19)31081-6 pmid: 30689702
[52]	SUNDAR R, BARR KUMARAKULASINGHE N, HUAK CHAN Y, et al. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase Ⅲ SAMIT trial[J]. Gut, 2022, 71(4): 676-685. doi: 10.1136/gutjnl-2021-324060
[53]	KATHER J N, PEARSON A T, HALAMA N, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer[J]. Nat Med, 2019, 25(7): 1054-1056. doi: 10.1038/s41591-019-0462-y pmid: 31160815
[54]	CHEN Q Y, XIE J W, ZHONG Q, et al. Safety and efficacy of indocyanine green tracer-guided lymph node dissection during laparoscopic radical gastrectomy in patients with gastric cancer: a randomized clinical trial[J]. JAMA Surg, 2020, 155(4): 300-311. doi: 10.1001/jamasurg.2019.6033
[55]	CHEN Q Y, ZHONG Q, LIU Z Y, et al. Indocyanine green fluorescence imaging-guided versus conventional laparoscopic lymphadenectomy for gastric cancer: long-term outcomes of a phase 3 randomised clinical trial[J]. Nat Commun, 2023, 14(1): 7413.

Surgical scope	Case characteristic	Study name	Study design	Major investigator	Case N	Primary study endpoint
Distal stomach	Early gastric cancer	KLASS-01^[16]	Stage Ⅲ RCT	Woo Jin Hyung (Yonsei University)	1 416	5-year disease-free survival rate
		JCOG0912^[17]	Stage Ⅲ RCT	Hitoshi Katai (National Cancer CenterJapan)	921	Recurrence-free survival
	Advanced gastric carcinoma	CLASS-01^[18]	Stage Ⅲ RCT	LI Guoxin (Nanfang Hospital, Southern Medical University)	1 039	3-year recurrence-free survival rate
Whole stomach	Early gastric cancer	CLASS-02^[21]	Stage Ⅲ RCT	SUN Yihong (Zhongshan University, Fudan University)	227	Postoperative complication rate and mortality
		KLASS-03^[19]	Stage Ⅱ single-arm study	Gyu Seok Cho (Soonchunhyang University)	160	Postoperative complication rate and mortality
		JCOG1401^[20]	Stage Ⅱ single-arm study	Hitoshi Katai (National Cancer CenterJapan)	195	Postoperative complication rate and mortality
	Advanced gastric carcinoma	CLASS-07	Stage Ⅲ RCT	SUN Yihong (Zhongshan University, Fudan University)	1 316	OS
		KLASS-06	Stage Ⅲ RCT	Woo Jin Hyung (Yonsei University)	772	3-year recurrence-free survival rate